189 related articles for article (PubMed ID: 22105711)
1. Effects of point mutations in pVHL on the binding of HIF-1α.
Domene C; Illingworth CJ
Proteins; 2012 Mar; 80(3):733-46. PubMed ID: 22105711
[TBL] [Abstract][Full Text] [Related]
2. Simulation of the mutation F76del on the von Hippel-Lindau tumor suppressor protein: mechanism of the disease and implications for drug development.
Limaverde-Sousa G; Barreto Ede A; Ferreira CG; Casali-da-Rocha JC
Proteins; 2013 Feb; 81(2):349-63. PubMed ID: 23011899
[TBL] [Abstract][Full Text] [Related]
3. Proline hydroxylation at different sites in hypoxia-inducible factor 1α modulates its interactions with the von Hippel-Lindau tumor suppressor protein.
Qian H; Zou Y; Tang Y; Gong Y; Qian Z; Wei G; Zhang Q
Phys Chem Chem Phys; 2018 Jul; 20(27):18756-18765. PubMed ID: 29961792
[TBL] [Abstract][Full Text] [Related]
4. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
5. STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination.
Jung JE; Kim HS; Lee CS; Shin YJ; Kim YN; Kang GH; Kim TY; Juhnn YS; Kim SJ; Park JW; Ye SK; Chung MH
Exp Mol Med; 2008 Oct; 40(5):479-85. PubMed ID: 18985005
[TBL] [Abstract][Full Text] [Related]
6. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
Liu J; Nussinov R
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):901-6. PubMed ID: 18195360
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
8. Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1alpha.
Illingworth CJ; Loenarz C; Schofield CJ; Domene C
Biochemistry; 2010 Aug; 49(32):6936-44. PubMed ID: 20695530
[TBL] [Abstract][Full Text] [Related]
9. Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex.
Dong X; Su X; Yu J; Liu J; Shi X; Pan Q; Yang J; Chen J; Li L; Cao H
J Mol Graph Model; 2017 Jan; 71():116-123. PubMed ID: 27902963
[TBL] [Abstract][Full Text] [Related]
10. USP9X destabilizes pVHL and promotes cell proliferation.
Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
[TBL] [Abstract][Full Text] [Related]
11. Role of Ran-regulated nuclear-cytoplasmic trafficking of pVHL in the regulation of microtubular stability-mediated HIF-1α in hypoxic cardiomyocytes.
Jiang X; Zhang D; Zhang H; Huang Y; Teng M
Sci Rep; 2015 Mar; 5():9193. PubMed ID: 25779090
[TBL] [Abstract][Full Text] [Related]
12. In silico investigation of PHD-3 specific HIF1-α proline 567 hydroxylation: a new player in the VHL/HIF-1α interaction pathway?
Minervini G; Masiero A; Moro S; Tosatto SC
FEBS Lett; 2013 Sep; 587(18):2996-3001. PubMed ID: 23886708
[TBL] [Abstract][Full Text] [Related]
13. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
14. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
15. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL
Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
17. Quantifying the Binding Interaction between the Hypoxia-Inducible Transcription Factor and the von Hippel-Lindau Suppressor.
Domene C; Jorgensen C; Vanommeslaeghe K; Schofield CJ; MacKerell A
J Chem Theory Comput; 2015 Aug; 11(8):3946-54. PubMed ID: 26574473
[TBL] [Abstract][Full Text] [Related]
18. Immunoexpression patterns for Hypoxia-inducible Factor-1α and von Hippel-Lindau protein, in relation to Hsp90, of human brain tumors.
Assimakopoulou M; Androutsopoulou C; Zolota V; Matsoukas J
Histol Histopathol; 2016 May; 31(5):535-46. PubMed ID: 26592496
[TBL] [Abstract][Full Text] [Related]
19. Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes.
Lee SH; Che X; Jeong JH; Choi JY; Lee YJ; Lee YH; Bae SC; Lee YM
J Biol Chem; 2012 Apr; 287(18):14760-71. PubMed ID: 22351759
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]